Evidence map›Paper›PMID 28295312›Full record

Observational studyJournal of child psychology and psychiatry, and allied disciplines2017

Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression.

James M Swanson, L Eugene Arnold, Brooke S G Molina, Margaret H Sibley, Lily T Hechtman, Stephen P Hinshaw, Howard B Abikoff, Annamarie Stehli, Elizabeth B Owens, John T Mitchell and 21 more

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of child psychology and psychiatry, and allied disciplines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 10 pooled it
22.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 10 syntheses or guidelines pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies.The International journal of risk & safety in medicine · 2017
    Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 20 institutions in 4 countries.

James M SwansonDepartment of Pediatrics, School of Medicine, University of California, Irvine, CA, USA.
L Eugene ArnoldDepartment of Psychiatry, Nisonger Center, Ohio State University, Columbus, OH, USA.
Brooke S G MolinaDepartments of Psychiatry and Psychology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Margaret H SibleyDepartment of Psychiatry, Florida International University, Miami, FL, USA.
Lily T HechtmanDivision of Child Psychiatry, McGill University, Montreal Children's Hospital, Montreal, QC, Canada.
Stephen P HinshawDepartment of Psychology, University of California, Berkeley, CA, USA.
Howard B AbikoffChild Study Center at New York University Langone Medical Center, New York, NY, USA.
Annamarie StehliDepartment of Pediatrics, School of Medicine, University of California, Irvine, CA, USA.
Elizabeth B OwensInstitute of Human Development, University of California, Berkeley, CA, USA.
John T MitchellDepartment of Psychiatry & Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.
Quyen NicholsDepartment of Psychological Science, University of Vermont, Burlington, VT, USA.
Andrea HowardDepartment of Psychology, Carleton University, Ottawa, ON, Canada.
Laurence L GreenhillDepartment of Psychiatry, Columbia University, New York, NY, USA.
Betsy HozaDepartment of Psychological Science, University of Vermont, Burlington, VT, USA.
Jeffrey H NewcornDepartment of Psychiatry, Mount Sinai Medical School, New York, NY, USA.
Peter S JensenDepartment of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Benedetto VitielloNational Institute of Mental Health, Bethesda, MD, USA.
Timothy WigalAvida, Inc., Newport Beach, CA, USA.
Jeffery N EpsteinDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Leanne TammDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Kimberly D LakesDepartment of Pediatrics, School of Medicine, University of California, Irvine, CA, USA.
James WaxmonskyPenn State University, College of Medicine, Hershey, PA, USA.
Marc LernerDepartment of Pediatrics, School of Medicine, University of California, Irvine, CA, USA.
Joy EtcovitchMontreal Children's Hospital, Montreal, QC, Canada.
Desiree W MurrayFrank Porter Graham Child Development Institute, University of North Carolina, Chapel Hill, NC, USA.
Maximilian MuenkeNational Human Genome Research Institute, Bethesda, MD, USA.
Maria T AcostaNational Human Genome Research Institute, Bethesda, MD, USA.
Mauricio Arcos-BurgosInstitute of Translational Medicine, Universidad del Rosario, Bogata, Colombia.
William E PelhamDepartment of Psychology, Florida International University, Miami, FL, USA.
Helena C KraemerDepartment of Psychiatry, Stanford University, Stanford, CA, USA.
MTA Cooperative Group
University of California, Irvine · USCincinnati Children's Hospital Medical Center · USFlorida International University · USNational Human Genome Research Institute · USUniversity of California, Berkeley · USUniversity of Vermont · USCarleton University · CAChild Development Center · QAColumbia University · USDuke University Hospital · USMcGill University · CAMontreal Children's Hospital · CAMount Sinai Medical Center · USNational Institute of Mental Health · USNYU Langone Health · USPacific Research Group (United States) · USPenn State Milton S. Hershey Medical Center · USStanford University · USThe Ohio State University Wexner Medical Center · USUniversidad del Rosario · CO

Funding

Genetic Analysis of Attention Deficit Hyperactivity DisorderZIAHG000175 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI SHAW, PHILIP · 2009 to 2025
$13.4M
Research_ProjectU54HD090257 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI VITTORIO GALLO, VITTORIO GALLO VITTORIO GALLO · 2016 to 2020
$5.9M
Pathways to adult substance use and abuse from childhood ADHD in the MTAR01DA039881 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MOLINA, BROOKE S.G. · 2015 to 2018
$1.1M
Emotion Dysregulation, ADHD, and SmokingK23DA032577 · NIDA · DUKE UNIVERSITY · PI MITCHELL, JOHN T · 2012 to 2015
$566k
PHARMACOLOGIC AND PSYCHOSOCIAL INTERVENTIONS FOR ADHDU01MH050461 · NIMH · UNIVERSITY OF CALIFORNIA BERKELEY · PI HINSHAW, STEPHEN P · 1992 to 2000
$17k
MULTISITE MULTIMODALITY TREATMENT STUDY OF ADHD/ADDU01MH050440 · NIMH · UNIVERSITY OF CALIFORNIA IRVINE · PI SWANSON, JAMES M · 1992 to 2000
$17k
MULTISITE MULTIMODAL TREATMENT STUDY OF ADHD/ADDU01MH050453 · NIMH · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ABIKOFF, HOWARD B · 1992 to 2000
$17k
PHARMACOLOGICAL AND PSYCHOSOCIAL TREATMENT FOR ADHDU01MH050467 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PELHAM, WILLIAM E · 1992 to 2000
$17k
FOLLOW-UP OF THE MULTIMODAL TREATMENT STUDY OF CHILDREN WITH ATTENTION-278012008N01MH012008 · NIMH · MCGILL UNIVERSITY · PI HECHTMAN, LILY T. · 2002 to 2006
–
FOLLOW UP OF THE MULTIMODAL TREATMENT STUDY OF CHILDREN WITH ATTENTION-278012007N01MH012007 · NIMH · RES. FOUND. FOR MENTAL HEALTH, · PI GREENHILL, LARRY LEE · 2002 to 2006
–
FOLLOW-UP OF THE MULTIMODAL TREATMENT STUDY OF CHILDREN WITH ATTENTION-278012009N01MH012009 · NIMH · UNIVERSITY OF CALIFORNIA, BERK · PI HINSHAW, STEPHEN · 2002 to 2006
–
FOLLOW-UP OF THE MULTIMODAL TREATMENT STUDY OF CHILDREN WITH ATTENTION-278012004N01MH012004 · NIMH · NEW YORK UNIVERSITY SCHOOL OF · PI ABIKOFF, HOWARD BARRY · 2002 to 2006
–
NICHD NIH HHS U54 HD090257NIDA NIH HHS HHSN271200800003CNIDA NIH HHS HHSN271200800005CNIDA NIH HHS HHSN271200800006CNIDA NIH HHS HHSN271200800007CNIDA NIH HHS HHSN271200800008CNIDA NIH HHS HHSN271200800009CNIDA NIH HHS K23 DA032577NIDA NIH HHS N01 DA085548NIDA NIH HHS N01 DA085549NIDA NIH HHS N01 DA085550NIDA NIH HHS N01 DA085551NIDA NIH HHS N01 DA085553NIDA NIH HHS N01 DA085554NIDA NIH HHS R01 DA039881NIMH NIH HHS N01 MH012004NIMH NIH HHS N01 MH012007NIMH NIH HHS N01 MH012008NIMH NIH HHS N01 MH012009NIMH NIH HHS N01 MH012010NIMH NIH HHS N01 MH012011NIMH NIH HHS N01 MH012012NIMH NIH HHS U01 MH050440NIMH NIH HHS U01 MH050453NIMH NIH HHS U01 MH050461NIMH NIH HHS U01 MH050467
6 · The paper itself

Abstract

backgroundThe Multimodal Treatment Study (MTA) began as a 14-month randomized clinical trial of behavioral and pharmacological treatments of 579 children (7-10 years of age) diagnosed with attention-deficit/hyperactivity disorder (ADHD)-combined type. It transitioned into an observational long-term follow-up of 515 cases consented for continuation and 289 classmates (258 without ADHD) added as a local normative comparison group (LNCG), with assessments 2-16 years after baseline.

methodsPrimary (symptom severity) and secondary (adult height) outcomes in adulthood were specified. Treatment was monitored to age 18, and naturalistic subgroups were formed based on three patterns of long-term use of stimulant medication (Consistent, Inconsistent, and Negligible). For the follow-up, hypothesis-generating analyses were performed on outcomes in early adulthood (at 25 years of age). Planned comparisons were used to estimate ADHD-LNCG differences reflecting persistence of symptoms and naturalistic subgroup differences reflecting benefit (symptom reduction) and cost (height suppression) associated with extended use of medication.

resultsFor ratings of symptom severity, the ADHD-LNCG comparison was statistically significant for the parent/self-report average (0.51 ± 0.04, p < .0001, d = 1.11), documenting symptom persistence, and for the parent/self-report difference (0.21 ± 0.04, p < .0001, d = .60), documenting source discrepancy, but the comparisons of naturalistic subgroups reflecting medication effects were not significant. For adult height, the ADHD group was 1.29 ± 0.55 cm shorter than the LNCG (p < .01, d = .21), and the comparisons of the naturalistic subgroups were significant: the treated group with the Consistent or Inconsistent pattern was 2.55 ± 0.73 cm shorter than the subgroup with the Negligible pattern (p < .0005, d = .42), and within the treated group, the subgroup with the Consistent pattern was 2.36 ± 1.13 cm shorter than the subgroup with the Inconsistent pattern (p < .04, d = .38).

conclusionsIn the MTA follow-up into adulthood, the ADHD group showed symptom persistence compared to local norms from the LNCG. Within naturalistic subgroups of ADHD cases, extended use of medication was associated with suppression of adult height but not with reduction of symptom severity.

Indexed as

Attention Deficit Disorder with HyperactivityBody HeightOutcome Assessment, Health CareSeverity of Illness IndexAdolescentAdultAftercareChildCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleYoung AdultAttention-deficit/hyperactivity disorderfollow-up studiesgrowthlongitudinal studiesmedication effectstreatment trials

Identifiers

PMID28295312
PMCPMC6168061
OpenAlexW2594813461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.